Acetyltanshinone IIA reduces the synthesis of cell cycle-related proteins by degrading p70S6K and subsequently inhibits drug-resistant lung cancer cell growth

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 68, 394, 10.3322/caac.21492 Gridelli, 2015, Non-small-cell lung cancer, Nat. Rev. Dis. Prim., 1, 1 Network, 2014, Comprehensive molecular profiling of lung adenocarcinoma, Nature, 511, 543, 10.1038/nature13385 Wu, 2020, Development of EGFR TKIs and options to manage resistance of third-generation EGFR TKI osimertinib: conventional ways and immune checkpoint inhibitors, Front. Oncol., 10, 2778, 10.3389/fonc.2020.602762 Yang, 2012, Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial, Lancet Oncol., 13, 539, 10.1016/S1470-2045(12)70086-4 Yu, 2014, Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing, Ann. Oncol., 25, 423, 10.1093/annonc/mdt573 Chong, 2013, The quest to overcome resistance to EGFR-targeted therapies in cancer, Nat. Med, 19, 1389, 10.1038/nm.3388 Zhou, 2009, Novel mutant-selective EGFR kinase inhibitors against EGFR T790M, Nature, 462, 1070, 10.1038/nature08622 Mok, 2017, Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer, New Engl. J. Med., 376, 629, 10.1056/NEJMoa1612674 Kim, 2015, Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor, J. Thorac. Oncol., 10, 1736, 10.1097/JTO.0000000000000688 Tetsu, 2016, Drug resistance to EGFR inhibitors in lung cancer, Chemotherapy, 61, 223, 10.1159/000443368 Massarelli, 2007, KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancer, Clin. Cancer Res, 13, 2890, 10.1158/1078-0432.CCR-06-3043 Takezawa, 2012, HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation, Cancer Disco, 2, 922, 10.1158/2159-8290.CD-12-0108 Sos, 2009, PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR, Cancer Res., 69, 3256, 10.1158/0008-5472.CAN-08-4055 de Bruin, 2014, Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer, Cancer Disco, 4, 606, 10.1158/2159-8290.CD-13-0741 Sequist, 2011, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors, Sci. Transl. Med., 3, 75ra26, 10.1126/scitranslmed.3002003 Xie, 2012, Activation of notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells, J. Cell Biochem., 113, 1501, 10.1002/jcb.24019 Taniguchi, 2008, Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib, Cancer Sci., 99, 929, 10.1111/j.1349-7006.2008.00782.x Engelman, 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, 316, 1039, 10.1126/science.1141478 Iwenofu, 2008, Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy, Mod. Pathol., 21, 231, 10.1038/modpathol.3800995 Neri, 2014, Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential, Leukemia, 28, 739, 10.1038/leu.2013.226 Fenton, 2011, Functions and regulation of the 70 kDa ribosomal S6 kinases, Int J. Biochem Cell Biol., 43, 47, 10.1016/j.biocel.2010.09.018 Bahrami-B, 2014, p70 Ribosomal protein S6 kinase (Rps6kb1): an update, J. Clin. Pathol., 67, 1019, 10.1136/jclinpath-2014-202560 Ip, 2012, Exploiting p70 S6 kinase as a target for ovarian cancer, Expert Opin. Ther. Targets, 16, 619, 10.1517/14728222.2012.684680 Filonenko, 2004, Immunohistochemical analysis of S6K1 and S6K2 localization in human breast tumors, Exp. Oncol., 26, 294 Nozawa, 2007, Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer, Cancer Lett., 251, 105, 10.1016/j.canlet.2006.11.008 Dhar, 2008, Constitutive activation of p70 S6 kinase is associated with intrinsic resistance to cisplatin, Int J. Oncol., 32, 1133 Liu, 2015, Active constituents in Danshen and their pharmacological actions, 49 Chien, 1978, Studies on the active principles of Dan-Shen—I. The structure of sodium tanshinone II-A sulfonate and methylene tanshinquinone, Acta Chim. Sin., 36, 199 Tian, 2007, A high throughput drug screen based on fluorescence resonance energy transfer (FRET) for anticancer activity of compounds from herbal medicine, Br. J. Pharmacol., 150, 321, 10.1038/sj.bjp.0706988 Tian, 2010, A novel compound modified from tanshinone inhibits tumor growth in vivo via activation of the intrinsic apoptotic pathway, Cancer Lett., 297, 18, 10.1016/j.canlet.2010.04.020 Huang, 2020, Acetyltanshinone IIA is more potent than lapatinib in inhibiting cell growth and degrading HER2 protein in drug-resistant HER2-positive breast cancer cells, Cancer Lett., 490, 1, 10.1016/j.canlet.2020.06.010 Pao, 2005, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib, PLoS Med., 2, 57 Pao, 2005, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, PLoS Med, 2, 225 Stewart, 2015, Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review, Transl. lung Cancer Res., 4, 67 Burslem, 2018, The advantages of targeted protein degradation over inhibition: an RTK case study, Cell Chem. Biol., 25, 67, 10.1016/j.chembiol.2017.09.009 Nagano, 2018, Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy, Cells, 7, 212, 10.3390/cells7110212 Sengupta, 2010, Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress, Mol. Cell, 40, 310, 10.1016/j.molcel.2010.09.026 Qin, 2015, Development of organometallic S6K1 inhibitors, J. Med Chem., 58, 305, 10.1021/jm5011868 Yu, 2014, A novel anti-cancer agent, acetyltanshinone IIA, inhibits oestrogen receptor positive breast cancer cell growth by down-regulating the oestrogen receptor, Cancer Lett., 346, 94, 10.1016/j.canlet.2013.12.023 Gartel, 2005, Lost in transcription: p21 repression, mechanisms, and consequences, Cancer Res, 65, 3980, 10.1158/0008-5472.CAN-04-3995 Morgan, 1997, Cyclin-dependent kinases: engines, clocks, and microprocessors, Annu Rev. Cell Dev. Biol., 13, 261, 10.1146/annurev.cellbio.13.1.261 Wu, 2018, Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells, Nat. Commun., 9, 1 Fu, 2007, Roles of Aurora kinases in mitosis and tumorigenesis, Mol. Cancer Res, 5, 1, 10.1158/1541-7786.MCR-06-0208 Gong, 2019, Aurora A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene, Cancer Disco, 9, 248, 10.1158/2159-8290.CD-18-0469 Shah, 2019, Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer, Nat. Med, 25, 111, 10.1038/s41591-018-0264-7 Lane, 1993, p70 s6k function is essential for G1 progression, Nature, 363, 170, 10.1038/363170a0 Feng, 2000, Stem cell factor/c-kit up-regulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia, J. Biol. Chem., 275, 25572, 10.1074/jbc.M002218200 Choudhury, 2010, A robust automated measure of average antibody staining in immunohistochemistry images, J. Histochem Cytochem, 58, 95, 10.1369/jhc.2009.953554 Morgillo, 2016, Mechanisms of resistance to EGFR-targeted drugs: lung cancer, ESMO Open, 1, 10.1136/esmoopen-2016-000060 Cheung, 2013, Survivin–biology and potential as a therapeutic target in oncology, Onco Targets Ther., 6, 1453, 10.2147/OTT.S33374 Akar, 2010, Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model, Mol. Cancer Ther., 9, 1180, 10.1158/1535-7163.MCT-09-1025 Dhar, 2008, Constitutive activation of p70 S6 kinase is associated with intrinsic resistance to cisplatin, Int J. Oncol., 32, 1133 Tolcher, 2014, A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours, Eur. J. Cancer, 50, 867, 10.1016/j.ejca.2013.11.039 Du, 2021, Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy, Mol. Cancer, 20, 1, 10.1186/s12943-020-01305-3